Planet Labs PBC (PL) declined approximately 16.7% over the last 30 days, with the closing price dropping from $31.15 on June 12 to $25.96 on July 13, continuing a sharp retreat from its all-time high of $51.76 reached in late May. The primary catalyst was a post-earnings selloff following the June 4 fiscal Q1 2027 report, where a $1.5 billion at-the-market equity offering announcement triggered dilution fears despite better-than-expected revenue and EPS results.

Ichor Holdings shares traded at $90.41 as of July 13, 2026, gaining approximately 4% over the prior 30 days amid continued semiconductor equipment demand momentum. First quarter 2026 revenue reached $256.1 million, exceeding analyst expectations, while non-GAAP EPS of $0.15 beat the consensus estimate of $0.13.

The Baldwin Insurance Group (BWIN) surged approximately 50.7% over the last 30 days, driven by reports the company is exploring strategic options including a potential take-private transaction. JPMorgan upgraded BWIN to Overweight from Neutral and raised its price target to $30, reinforcing bullish sentiment around the stock.

LifeStance Health Group (LFST) surged approximately 28% over the last 30 days, climbing from $8.50 on June 12 to $10.88 by July 13, 2026. Strong Q1 2026 earnings reported in early May continued to reverberate, with revenue up 21% year-over-year to $403.5 million and EPS of $0.04 beating consensus estimates by 300%.

Relay Therapeutics (RLAY) surged approximately 26% over the past 30 days, climbing from around $14.81 on June 12 to $18.73 as of July 13, 2026, driven by a series of compelling clinical data readouts and analyst upgrades. The stock's rally was propelled by positive Phase 2 data for zovegalisib in vascular anomalies showing a 60% volumetric response rate, far exceeding the 11%–20% historical benchmark.

Apple (AAPL) recently traded near $317 per share, with a 52-week high of approximately $323, putting the $350 target roughly 10% above current levels. Strong early demand for the iPhone 17 lineup, a massive installed base of users overdue for upgrades, and accelerating Services revenue represent the strongest bullish catalysts.

Aehr Test Systems is scheduled to report fiscal 2026 fourth quarter and full year results on July 14, 2026, after market close. Analysts expect the company to deliver revenue on the high end of its $45 million to $50 million full-year guidance range.

Ericsson is scheduled to release its second quarter 2026 results on July 14, 2026. Analysts expect earnings per share around $0.13 for the quarter.

América Móvil is scheduled to report second-quarter 2026 financial and operating results after market close on July 21, with a conference call the following day. Analysts are focused on revenue trends in the company's core wireless and fixed-line segments across Latin America.

Cardinal Infrastructure Group (CDNL) shares have pulled back roughly 6% over the last 30 days, settling near $64 after an extraordinary run to above $94 in late June. The stock has exhibited pronounced volatility characteristic of a recently public small-cap company, with a June rally giving way to sharp profit-taking in early July.

Pattern Group (PTRN) shares surged approximately 34% over the last 30 days, rising from $20.96 on June 12 to an intraday high of $29.63 in the most recent session. The rally was fueled by inclusion in the Russell 3000 and Russell 2000 indexes, a bullish Goldman Sachs price target increase, and the launch of the Pattern Intelligence (Pi) AI platform.

Life360 (LIF) shares gained approximately 16% over the last 30 days, rising from around $45.25 to $52.32, as of intraday trading on July 13, 2026. The stock has surged roughly 32% over the past quarter, reflecting accelerating revenue growth, advertising momentum, and improving investor sentiment.

10x Genomics shares surged roughly 44% over the past 30 days, climbing from approximately $28.84 to $41.60 and repeatedly touching new 52-week highs. The rally was fueled by a series of catalysts including the acquisition of Proteintech Genomics, a multi-year research partnership with Cleveland Clinic, and a wave of analyst price target increases.

Dave Inc. (DAVE) surged approximately 36.9% over the past 30 days, rising from $286.78 on June 12 to $392.49 on July 13, 2026. The rally extends a powerful multi-month uptrend, with DAVE more than doubling over the last quarter from roughly $173 in early April.

SHAZ shares tumbled approximately -12.95% during regular trading on Monday to around $64.96, extending a multi-session sell-off from the prior Friday close of $74.62. The decline appears driven by sustained competitive fears following recent reports that Meta is advancing its "Meta Compute" initiative to sell excess AI compute capacity, directly challenging neocloud providers like SharonAI.

PHAT shares dropped -12.13% during Monday's regular session, falling to around $11.08 after closing at $12.61 the prior Friday, erasing nearly all gains from the prior week's rally. The decline appears driven by profit-taking following a sharp ~20% surge over the previous five sessions, with no specific negative company news or fundamental catalyst identified.

TSHA shares are down approximately -14.20% to around $5.44 during regular trading hours on Monday, extending Friday's -3.50% decline. The selloff was triggered by fallout from a pre-arranged insider sale disclosed Friday, in which the President and Head of R&D sold 200,000 shares worth ~$1.25M under a Rule 10b5-1 plan.

AXT, Inc. (AXTI) shares have plunged approximately 50% over the past 30 days, falling from $97.18 on June 12 to $48.55 as of mid-July 2026, marking one of the sharpest corrections in the semiconductor substrate sector. The selloff represents a dramatic momentum unwind after the stock surged from roughly $2 in early 2025 to an all-time high of $143.16 in late May 2026, driven by AI-fueled demand for indium phosphide (InP) wafers.

Price target examined: $10 per share, a psychologically significant round number that sits roughly 87% above recent trading levels and above the 52-week high of $8.60. Strongest bullish factors: Dramatic share price recovery from the $0.39 low, new CEO-led strategic pivot toward AI and hybrid cloud services, and high-profile partnerships with AMD and Palantir.

RXT shares dropped -16.32% during Monday's regular session, extending the stock's volatile swings after Friday's +22% bounce from the prior week's guidance-cut rout. The selloff reflects continued fallout from the July 9 preliminary Q2 results that slashed FY2026 revenue guidance by $150M to $2.45B-$2.55B and cut EBITDA targets by $20M to $285M-$295M.